Hematologic Oncology | Specialty

Triggers to Initiate Therapy for Follicular Lymphoma

August 15th 2017

Risk Stratifying Patients With Follicular Lymphoma

August 15th 2017

Follicular Lymphoma: Diagnosis and Staging

August 15th 2017

Dr. Erba on the FDA Approval of CPX-351 in AML

August 11th 2017

Harry Erba, MD, PhD, professor of medicine, director, University of Alabama (UAB) Hematologic Malignancy Program, UAB School of Medicine, sheds light on the FDA approval of CPX-351 (Vyxeos) in acute myeloid leukemia (AML).

Higher Bortezomib Doses Linked to Longer OS in MCL

August 10th 2017

Patients with newly diagnosed mantle cell lymphoma assigned to frontline chemotherapy had a survival advantage when they were able to receiver higher dose intensities of bortezomib (Velcade).

SF3B1 Mutation Associated With Poor Survival in CLL

August 8th 2017

Researchers in China have concluded that mutation of the SF3B1 gene is “significantly associated” with poorer progression-free survival and overall survival in patients with chronic lymphocytic leukemia.

MRD Associated With Poorer Survival Following ASCT in MCL

August 7th 2017

Long-term results from the Nordic MCL2 and MCL3 trials showed patients with mantle cell lymphoma who are positive for minimal residual disease following allogenic stem cell transplant had significantly shorter survival.

Dr. Roboz on Challenges With CAR T-cell Therapy in ALL

August 4th 2017

Gail Roboz, MD, a professor of Medicine and director of the Clinical and Translational Leukemia Program at Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses the challenges clinicians are facing with chimeric antigen receptor (CAR) T-cell therapy in acute lymphoblastic leukemia (ALL).

Writing the Book on Cancer Care: Holland Reminisces

August 4th 2017

James F. Holland, MD, reminisces on nearly 70 years of practicing medicine.

XPO1 Inhibitor Offers Novel Mechanism for Treating Penta-Refractory Myeloma

August 3rd 2017

Selinexor (KPT-330), a small-molecule inhibitor with a novel mechanism of action, is being investigated in patients with multiple myeloma who have become refractory to the many new options that have been introduced in recent years for patients with the malignancy.

Dr. Ansell on Combining CAR T-cell Therapy and Immunotherapy in Lymphomas

August 3rd 2017

Stephen M. Ansell, MD, PhD, chair of the Lymphoma Group at Mayo Clinic, discusses the possibility of blending immunotherapy agents with chimeric antigen receptor (CAR) T-cell therapy across lymphoma populations.

FDA Approves CPX-351 for Two Types of AML

August 3rd 2017

The FDA has approved CPX-351 for adult patients with newly diagnosed therapy-related acute myeloid leukemia or AML with myelodysplasia-related changes.

FDA Awards Acalabrutinib Priority Review in MCL

August 2nd 2017

The FDA has granted a priority review to a new drug application for acalabrutinib for patients with previously-treated mantle cell lymphoma.

FDA Approves Ibrutinib for GVHD

August 2nd 2017

The FDA has approved ibrutinib for the treatment of adult patients with chronic graft versus host disease following the failure of 1 or more lines of systemic therapy. The BTK inhibitor is now the first FDA-approved therapy for the treatment of cGVHD.

Dr. Al-Kali on FDA Approval of Enasidenib in AML

August 1st 2017

Aref Al-Kali, MD, hematologist, oncologist, Mayo Clinic, discusses the FDA approval of enasidenib as a treatment for patients with relapsed or refractory IDH2-mutated acute myeloid leukemia (AML).

FDA Approves Enasidenib for IDH2-Mutated AML

August 1st 2017

The FDA has approved enasidenib along with a companion diagnostic as a treatment for patients with relapsed or refractory IDH2-mutated acute myeloid leukemia.

CD19 CAR T-Cell Therapy Active in Ibrutinib-Refractory CLL

July 31st 2017

Treatment with CD19 chimeric antigen receptor-modified T-cell therapy induced a high response rate in patients with high-risk, ibrutinib-refractory chronic lymphocytic leukemia.

Emerging Developments in CML

July 29th 2017

Kendra Sweet, MD, discusses the various factors that must be taken into account when prescribing first-line therapies to patients with CML, novel studies, and TKI discontinuation.

FDA Grants Venetoclax Breakthrough Designation for AML Subpopulation

July 29th 2017

Venetoclax has received an FDA breakthrough therapy designation for use in combination with low dose cytarabine in treatment-naïve elderly patients with acute myeloid leukemia who are ineligible for intensive chemotherapy.

Expert Discusses Latest Developments in MPNs

July 26th 2017

Rami Komrokji, MD, shares his insight on the various types of MPNs, how these diseases can be diagnosed and managed, and the next steps needed to improve patient outcomes.